Revelation Biosciences
REVB
12 hedge funds and large institutions have $313K invested in Revelation Biosciences in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
5.65% less ownership
Funds ownership: 13.43% → 7.79% (-5.6%)
48% less capital invested
Capital invested by funds: $600K → $313K (-$287K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$121K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$41.9K |
| 3 |
HF
HRT Financial
New York
|
+$18.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.66K |
| 5 |
Barclays
London,
United Kingdom
|
+$182 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$388K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$28.2K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$13.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $217K | +$121K | +111,150 | +112% |
|
|
2
Citadel Advisors
Miami,
Florida
| $39.7K | +$41.9K | +38,579 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $17.7K | -$28.2K | -26,003 | -60% |
|
|
HF
4
HRT Financial
New York
| $17K | +$18.4K | +16,978 | New |
|
5
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $13.5K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $6.72K | +$2.66K | +2,454 | +60% |
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
SS
8
SBI Securities
Tokyo,
Japan
| $354 | – | – | – |
|
|
9
Barclays
London,
United Kingdom
| $173 | +$182 | +168 | New |
|
|
HI
10
Harbour Investments
Madison,
Wisconsin
| $42 | – | – | – |
|
11
BNP Paribas Asset Management
Paris,
France
| $9 | – | – | – |
|
|
CIAM
12
Caitong International Asset Management
Hong Kong
| $1 | – | – | – |
|
|
AC
13
Armistice Capital
New York
| – | -$388K | -323,241 | Closed |
|
|
XT
14
XTX Topco
George Town,
Cayman Islands
| – | -$13.7K | -11,385 | Closed |
|
|
15
UBS Group
Zurich,
Switzerland
| – | -$4.94K | -4,115 | Closed |
|
REVB Hedge Fund Activity: Q2 2026 in Review
12 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q2 2026, worth a combined $313K — down 48% from $600K a quarter earlier.
Fund positioning in REVB was balanced in Q2 2026: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, adding an estimated $121K. The largest seller was Armistice Capital, exiting entirely with an estimated $388K sold.
- 12 institutional investors held Revelation Biosciences (REVB) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $313K of Revelation Biosciences stock for Q2 2026, down 48% quarter-over-quarter.
- 3 funds opened new Revelation Biosciences positions in Q2 2026 and 3 closed out, a net change of 0 holders.
- The largest Revelation Biosciences buyer in Q2 2026 was Sabby Management, an estimated $121K added.
- The largest Revelation Biosciences seller in Q2 2026 was Armistice Capital, an estimated $388K sold.
Based on aggregated 13F filings for Q2 2026.